Daniela Grabs, PhD Co-Founder, CSO

Daniela Grabs co-founded Arzeda and currently serves as its Chief Scientific Officer. Her responsibilities include overseeing the experimental validation and protein optimization lab in addition to her contributions to the core design technology. She has worked to enable an industrial strength research and development platform going from computational design through designer cell factories as efficiently as possible with minimal human intervention. Daniela believes that given enough time and resources, a bio-based economy will transform the chemical industry with better keystone building block molecules. Daniela holds a Ph.D. in Biochemistry from the University of Zürich and a Diploma from ETH Zürich.


Alexandre Zanghellini, PhD Co-Founder, CEO

Alexandre Zanghellini is a co-founder of Arzeda and serves as its Chief Executive Officer. Along with Arzeda’s management team, he is responsible for day-to-day operations and also leads Arzeda’s product and technology development and IP strategy. Alex is one of the inventors of Arzeda’s synthetic biology platform for novel enzyme and metabolic pathway design and is a keen believer in the power of biotechnology to solve some of our biggest societal challenges. Before founding Arzeda, Alex held positions in research and development both in academia and industry. He holds a Ph.D. from the University of Washington and a M.Sc. Eng. from ENSTA/ParisTech in Paris, France.

Eric Althoff, PhD Co-Founder, CBO

Eric Althoff co-founded Arzeda and serves as its Chief Business Officer. After an extensive chemistry background, he subsequently discovered the utility of enzyme catalysis and the power of biological solutions and has been hooked on the pursuit of engineering of biological systems. Eric leads Arzeda’s business development and technology outreach to identify partners and opportunities to which to apply Arzeda’s technology. His experience with applying computational design to design beyond the solutions available in Nature have helped to build a world leading technology platform at Arzeda. By applying Arzeda’s technology, materials and proteins with improved properties can be enabled to improve upon the existing petrochemical processes. An avid cyclist and backpacker, his commitment to a sustainable future is a lifetime passion. Eric holds a Ph.D. in Chemistry from Columbia University and an S.M. in Chemistry from the University of Chicago.

Michael Martino Board of Directors

Mr. Martino has served as president and chief executive officer of Ambit since November 2011. From March 2010 until November 2011, Mr. Martino held multiple positions with CareFusion Corporation, a publicly-traded healthcare company, including senior vice president and general manager of diagnostics and senior vice president of innovation, business development and strategy.

From January 2009 to March 2010, Mr. Martino was president and chief executive officer of Arzeda Corp, and he remains on the board of directors. From September 1998 to August 2008, Mr. Martino served as president and chief executive officer of Sonus Pharmaceuticals a publicly-traded pharmaceutical development company that merged with Oncogenex Pharmaceuticals in August 2008.

Earlier in his career, he held multiple positions during a 17-year tenure at Mallinckrodt, Inc., in strategic planning, business development, marketing and general management. Mr. Martino received an M.B.A. from Virginia Tech and a B.A. from Roanoke College.

Thong Q. Le Board of Directors

Mr. Le focuses on investment opportunities in biopharmaceuticals, medical devices, enterprise software and advanced materials. He has worked closely with the management teams and boards of Corus Pharma (acquired by Gilead Sciences), Lumera (Nasdaq NM:LMRA), Performant (acquired by Mercury Interactive), and Point of CareWare.

He currently represents WRF Capital as a Director of Accelerator, Arzeda, GPC-Rx and Mirina, and is a Board Observer at Alder Biopharmaceuticals, Halosource, Hyperion Therapeutics, Pathway Medical Technologies, Teranode, Uptake Medical, and VLST.

Prior to joining WRF Capital, Mr. Le was the founder, president and chief executive officer of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.

Mr. Le completed post-graduate studies at the Templeton College of Oxford University and earned a bachelor of arts cum laude in economics and government from Harvard University. He also serves on the executive boards of the Evergreen Venture Capital Association (EVCA), the Washington Biotechnology & Biomedical Association (WBBA), and the Harvard Club of Seattle.

Professor Bernhard Hauer, PhD Scientific Advisory Board

Dr. Bernhard Hauer is head of the Institute of Technical Biochemistry and professor at the University of Stuttgart. His research focuses on expanding nature’s portfolio of chemical reactions by designing novel enzymes and biosynthetic routes. Prior to his university career he was Vice President of Research and head of the biocatalysis research group at BASF SE, Ludwigshafen. He obtained a degree in molecular biology at the University of Heidelberg. His post-doctoral training was with J.A. Shapiro at the University of Chicago, after receiving his Ph.D. with F. Lingens in microbiology from the University of Hohenheim, Stuttgart. He is active on several advisory boards, editorial boards as well as scientific societies.

Professor David Baker, PhD Co-Founder & Scientific Advisory Board

Dr. David Baker is Professor of Biochemistry, Bioengineering and Genome Sciences at the University of Washington and Howard Hughes Medical Institute investigator.

Dr. Baker is regarded as the world-leading expert in computational protein structure prediction and design. He is a member of the National Academy of Sciences, one of the world’s highest rewards for scientific excellence and the recipient of numerous awards, including the Foresight Institute’s Feynman Prize, the AAAS Newcomb Cleveland Prize, the International Society for Computational Biology Overton Prize, and the Raymond and Beverly Sackler International Prize in Biophysics.

Dr. Baker’s current research goals are to predict the structures of naturally occurring biomolecules and interactions and to design new molecules with new and interesting functions.